The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development (Q38728567)

5 September 2017

1 reference

title

The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development (English)

1 reference

5 September 2017

1 reference

Jun Gong

1

1 reference

5 September 2017

Gauri Kelekar

2

1 reference

5 September 2017

James Shen

3

1 reference

5 September 2017

John Shen

4

1 reference

5 September 2017

Sukhpreet Kaur

5

1 reference

5 September 2017

Monica Mita

6

1 reference

5 September 2017

11 February 2016

1 reference

5 September 2017

1 reference

5 September 2017

11

1 reference

5 September 2017

447-467

1 reference

5 September 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1007/s11523-016-0423-z

5 September 2017

0 references

cites work

The blooming of the French lilac

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Understanding the benefit of metformin use in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin as an antitumor agent in cancer prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin and reduced risk of cancer in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Investigating metformin for cancer prevention and treatment: the end of the beginning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Brain cancer stem cells display preferential sensitivity to Akt inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

PTEN, stem cells, and cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Very high risk of cancer in familial Peutz-Jeghers syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

AMP-activated protein kinase signaling in metabolic regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

TSC2 mediates cellular energy response to control cell growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin in cancer: translational challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin: taking away the candy for cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Role of AMP-activated protein kinase in mechanism of metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Mechanistic target of rapamycin (mTOR): a point of convergence in the action of insulin/IGF-1 and G protein-coupled receptor agonists in pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Mechanisms by which low glucose enhances the cytotoxicity of metformin to cancer cells both in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin-induced energy deficiency leads to the inhibition of lipogenesis in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Prospective identification of tumorigenic breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Empowering self-renewal and differentiation: the role of mitochondria in stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin alters the expression profiles of microRNAs in human pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin reduces endogenous reactive oxygen species and associated DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Inhibition of the GTPase Rac1 mediates the antimigratory effects of metformin in prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Mechanism of the mitogenic influence of hyperinsulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Insulin-like growth factors and neoplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Diabetes, pancreatic cancer, and metformin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Diabetes and breast cancer risk: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Diabetes mellitus and risk of prostate cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

The role of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence and prognosis: a meta-analysis of prospective cohort studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Combined randomised controlled trial experience of malignancies in studies using insulin glargine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Systematic review and meta-analysis of insulin therapy and risk of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Insulin use and cancer risk in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Association of metformin use with cancer incidence and mortality: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Association between metformin therapy and incidence, recurrence and mortality of prostate cancer: evidence from a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin use and lung cancer risk in patients with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Survival of patients with stage IV lung cancer with diabetes treated with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Effects of metformin on head and neck cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Survival benefits of metformin for colorectal cancer patients with diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin is associated with improved survival in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin and breast cancer risk: a meta-analysis and critical literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

The effects of metformin on ovarian cancer: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Influence of metformin intake on the risk of bladder cancer in type 2 diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Prevention of pancreatic cancer induction in hamsters by metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin decreases growth of pancreatic cancer cells by decreasing reactive oxygen species: Role of NOX4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Radiosensitization of metformin in pancreatic cancer cells via abrogating the G2 checkpoint and inhibiting DNA damage repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Combination of Anti-Diabetic Drug Metformin and Boswellic Acid Nanoparticles: A Novel Strategy for Pancreatic Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin induces unique biological and molecular responses in triple negative breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin synergizes 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) combination therapy through impairing intracellular ATP production and DNA repair in breast cancer stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Combined Use of Metformin and Everolimus Is Synergistic in the Treatment of Breast Cancer Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin and breast cancer: basic knowledge in clinical context.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Increase in apoptosis by combination of metformin with silibinin in human colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Combined use of vitamin D3 and metformin exhibits synergistic chemopreventive effects on colorectal neoplasia in rats and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin: a potential therapeutic agent for recurrent colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Combined therapeutic effect and molecular mechanisms of metformin and cisplatin in human lung cancer xenografts in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

In vitro metformin anti-neoplastic activity in epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Vitamin D3 potentiates the growth inhibitory effects of metformin in DU145 human prostate cancer cells mediated by AMPK/mTOR signalling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Targeting stromal-induced pyruvate kinase M2 nuclear translocation impairs oxphos and prostate cancer metastatic spread.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Effect of Metformin, Rapamycin, and Their Combination on Growth and Progression of Prostate Tumors in HiMyc Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin inhibits the proliferation, metastasis, and cancer stem-like sphere formation in osteosarcoma MG63 cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin inhibits cell cycle progression of B-cell chronic lymphocytic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

The antileukemia effect of metformin in the Philadelphia chromosome-positive leukemia cell line and patient primary leukemia cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin potentiates rapamycin and cisplatin in gastric cancer in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Anti-tumor effects of metformin in animal models of hepatocellular carcinoma: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Proteomic characterization of harvested pseudopodia with differential gel electrophoresis and specific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Insulin-lowering effects of metformin in women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

The effect of metformin on apoptosis in a breast cancer presurgical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Effect of Metformin on Breast Ductal Carcinoma In Situ Proliferation in a Randomized Presurgical Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Effects of different doses of metformin treatment for 6 months on aberrant crypt foci in Chinese patients with impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

21 January 2018

The perfect arrangement.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Phase II trial of metformin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

A presurgical window-of-opportunity study of metformin in obesity-driven endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett's esophagus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

A phase I study of temsirolimus and metformin in advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin and cancer: mounting evidence against an association.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Metformin and the risk of cancer: time-related biases in observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0423-Z

Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study

21 January 2018

1 reference

12 December 2020

Metformin inhibits leptin-induced growth and migration of glioblastoma cells

1 reference

12 December 2020

Impact of metformin use on survival in locally-advanced, inoperable non-small cell lung cancer treated with definitive chemoradiation

1 reference

12 December 2020

Metformin potentiates the anticancer effects of cisplatin under normoxic conditions in vitro

1 reference

12 December 2020

Combination of metformin and valproic acid synergistically induces cell cycle arrest and apoptosis in clear cell renal cell carcinoma

1 reference

12 December 2020

Antiproliferative effect of metformin on the endometrium--a clinical trial.

1 reference

12 December 2020

Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults

1 reference

12 December 2020

Synthesis and antitumor activity of an inhibitor of fatty acid synthase

1 reference

12 December 2020

Physiological concentrations of insulin augment pancreatic cancer cell proliferation and glucose utilization by activating MAP kinase, PI3 kinase and enhancing GLUT-1 expression

1 reference

12 December 2020

Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.

1 reference

12 December 2020

Metformin and lung cancer risk of patients with type 2 diabetes mellitus: A meta-analysis

1 reference

12 December 2020

Combination simvastatin and metformin induces G1-phase cell cycle arrest and Ripk1- and Ripk3-dependent necrosis in C4-2B osseous metastatic castration-resistant prostate cancer cells.

1 reference

12 December 2020

Diabetes mellitus and the incidence and mortality of colorectal cancer: a meta-analysis of 24 cohort studies

1 reference

12 December 2020

(Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial.

1 reference

12 December 2020

Metformin Addition to Chemotherapy in Stage IV Non-Small Cell Lung Cancer: an Open Label Randomized Controlled Study.

1 reference

12 December 2020

Glycolytic glioma cells with active glycogen synthase are sensitive to PTEN and inhibitors of PI3K and gluconeogenesis

1 reference

12 December 2020

Do endometrial cancer patients benefit from metformin intake?

1 reference

12 December 2020

No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis

1 reference

12 December 2020

Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis

1 reference

12 December 2020

Combined 2-deoxy glucose and metformin improves therapeutic efficacy of sodium-iodide symporter-mediated targeted radioiodine therapy in breast cancer cells

1 reference

12 December 2020

Dual effect of metformin on growth inhibition and oestradiol production in breast cancer cells.

1 reference

12 December 2020

Insulin inhibits transcription of the human gene for insulin-like growth factor-binding protein-1

1 reference

12 December 2020

[The effect of metformin on responses to chemotherapy and survival in stage IV colorectal cancer with diabetes]

1 reference

12 December 2020

Antidiabetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo

1 reference

12 December 2020

Synergistic antitumor activity of vitamin D3 combined with metformin in human breast carcinoma MDA-MB-231 cells involves m-TOR related signaling pathways

1 reference

12 December 2020

Metformin suppresses sonic hedgehog expression in pancreatic cancer cells

1 reference

12 December 2020

10.1007/S11523-016-0423-Z

Identifiers

DOI

1 reference

Dimensions Publication ID

5 September 2017

0 references

1 reference